| # | Title | Journal | Year | Citations |
|---|
| 1 | An exploratory test for an excess of significant findings | Clinical Trials | 2007 | 555 |
| 2 | Meta-analysis of individual patient data from randomized trials: a review of methods used in practice | Clinical Trials | 2005 | 463 |
| 3 | Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals | Clinical Trials | 2004 | 417 |
| 4 | The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) | Clinical Trials | 2014 | 408 |
| 5 | Beyond the intention-to-treat in comparative effectiveness research | Clinical Trials | 2012 | 348 |
| 6 | Imputation methods for missing outcome data in meta-analysis of clinical trials | Clinical Trials | 2008 | 288 |
| 7 | Key cost drivers of pharmaceutical clinical trials in the United States | Clinical Trials | 2016 | 273 |
| 8 | Summarizing historical information on controls in clinical trials | Clinical Trials | 2010 | 257 |
| 9 | Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials | Clinical Trials | 2015 | 244 |
| 10 | Including all individuals is not enough: Lessons for intention-to-treat analysis | Clinical Trials | 2012 | 233 |
| 11 | Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care | Clinical Trials | 2004 | 230 |
| 12 | Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements | Clinical Trials | 2008 | 229 |
| 13 | Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research | Clinical Trials | 2005 | 225 |
| 14 | Design and analysis of clinical trials with clustering effects due to treatment | Clinical Trials | 2005 | 223 |
| 15 | National Institute of Neurological Disorders and Stroke Common Data Element Project – approach and methods | Clinical Trials | 2012 | 218 |
| 16 | Efficiencies of platform clinical trials: A vision of the future | Clinical Trials | 2016 | 209 |
| 17 | The intermediate endpoint effect in logistic and probit regression | Clinical Trials | 2007 | 201 |
| 18 | The role of measurement reliability in clinical trials | Clinical Trials | 2004 | 199 |
| 19 | Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine | Clinical Trials | 2008 | 199 |
| 20 | A modified toxicity probability interval method for dose-finding trials | Clinical Trials | 2010 | 187 |
| 21 | Statistical evaluation of learning curve effects in surgical trials | Clinical Trials | 2004 | 184 |
| 22 | Covariate-based constrained randomization of group-randomized trials | Clinical Trials | 2004 | 174 |
| 23 | Fallacies of last observation carried forward analyses | Clinical Trials | 2016 | 174 |
| 24 | Dynamic treatment regimes: practical design considerations | Clinical Trials | 2004 | 169 |
| 25 | Model calibration in the continual reassessment method | Clinical Trials | 2009 | 166 |
| 26 | The continual reassessment method for dose-finding studies: a tutorial | Clinical Trials | 2006 | 165 |
| 27 | Optimization of behavioral dynamic treatment regimens based on the sequential, multiple assignment, randomized trial (SMART) | Clinical Trials | 2014 | 165 |
| 28 | Bayesian hierarchical modeling of patient subpopulations: Efficient designs of Phase II oncology clinical trials | Clinical Trials | 2013 | 155 |
| 29 | Sensible approaches for reducing clinical trial costs | Clinical Trials | 2008 | 153 |
| 30 | Exploring the ethical and regulatory issues in pragmatic clinical trials | Clinical Trials | 2015 | 153 |
| 31 | Specific barriers to the conduct of randomized trials | Clinical Trials | 2008 | 144 |
| 32 | A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies | Clinical Trials | 2008 | 143 |
| 33 | Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials | Clinical Trials | 2009 | 143 |
| 34 | Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? | Clinical Trials | 2005 | 140 |
| 35 | A predictive probability design for phase II cancer clinical trials | Clinical Trials | 2008 | 140 |
| 36 | The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research | Clinical Trials | 2012 | 140 |
| 37 | Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials | Clinical Trials | 2005 | 134 |
| 38 | Development of the Stanford Expectations of Treatment Scale (SETS): A tool for measuring patient outcome expectancy in clinical trials | Clinical Trials | 2012 | 131 |
| 39 | Ensuring trial validity by data quality assurance and diversification of monitoring methods | Clinical Trials | 2008 | 129 |
| 40 | Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | Clinical Trials | 2010 | 128 |
| 41 | Introduction to Bayesian methods I: measuring the strength of evidence | Clinical Trials | 2005 | 123 |
| 42 | Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs | Clinical Trials | 2006 | 120 |
| 43 | Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors | Clinical Trials | 2006 | 118 |
| 44 | Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data | Clinical Trials | 2007 | 118 |
| 45 | The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? | Clinical Trials | 2007 | 116 |
| 46 | Evaluating the quality of informed consent | Clinical Trials | 2005 | 113 |
| 47 | Do we need to adjudicate major clinical events? | Clinical Trials | 2008 | 111 |
| 48 | Dose-finding in phase I clinical trials based on toxicity probability intervals | Clinical Trials | 2007 | 108 |
| 49 | Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team | Clinical Trials | 2009 | 107 |
| 50 | Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center | Clinical Trials | 2009 | 106 |
